CYTOPOINTTM is a novel monoclonal antibody (mAb) therapy conditionally licensed by the USDA to help reduce clinical signs associated with atopic dermatitis in dogs.
As a mAb, CYTOPOINTTM is specifically designed to target and neutralize cytokine IL-31, a key itch-inducing cytokine in canine atopic dermatitis. It interrupts the itch cycle, allowing dogs to stop scratching so damaged skin can heal
CYTOPOINTTM begins working within 1 day and delivers a month of relief from the clinical signs of canine atopic dermatitis. It is safe for dogs of all ages, even those with concomitant diseases, and can be used with many common medications.
CYTOPOINTTM is an injectable therapy that provides long lasting relief and helps improve the quality of life for dogs with atopic dermatitis and their owners.
- Targeted:Specifically targets and neutralizes interleukin (IL)-31, a key itch-inducing cytokine in atopic dermatitis.
- Works Fast and Lasts: Begins working within 1 day and delivers 4 to 8 weeks of relief from the clinical signs of atopic dermatitis.
In office administration ensures compliance.
- Safe: Safe for dogs of all ages, even those with concomitant diseases, and can be used with many common medications.
CYTOPOINTTM is available in single-use 1-mL vials in four concentrations: 10, 20, 30 or 40 mg/vial.
Administer at a minimum dose of 2.0 mg/kg body weight. For convenience, the dosing table may be used as a guideline.
Store vials upright, in original packing, at 2°-8°C/36°-47°F. Do not freeze. Prolonged exposure to higher temperature and/or direct sunlight may adversely affect potency
CYTOPOINTTM contains no preservatives and vials are single-use only. Vials should be discarded after puncture.